Lille University Hospital Center

Lille, France

Lille University Hospital Center

Lille, France
SEARCH FILTERS
Time filter
Source Type

Patent
Medizinische Hochschule Hanover, Institute Pasteur Of Lille Ipl and Lille University Hospital Center | Date: 2017-01-25

The present invention relates to a method for predicting mortality of a test patient with chronic heart failure comprising based on detecting the expression level of one or more long non-coding RNAs (IncRNAs) selected from SEQ ID NOs 1 to 8. The present invention also relates to a method for predicting cardiac remodeling after myocardial infarction in a test patient based on detecting the expression level of one or more IncRNAs selected from SEQ ID NOs 1 to 8.


Patent
Lille 2 University of Health, Law, French Institute of Health, Medical Research and Lille University Hospital Center | Date: 2015-06-11

The invention relates to compounds of formula (I) or the pharmaceutically acceptable solvates thereof, as well as to the use thereof as a drug.


Patent
Lille University Hospital Center, Lille 2 University of Health, Law and University of the Littoral Opal Coast | Date: 2015-05-12

The present invention is directed to pharmaceutical solution comprising at least dopamine for use in treating Parkinsons disease, wherein said pharmaceutical solution is kept under anaerobic conditions from its firmation to its administration.


Patent
Lille University Hospital Center | Date: 2017-02-22

The invention relates to an isolated monoclonal antibody that specifically binds to the D4 domain of VWF, competes for binding to VWF D4 domain with ADAMTS13 and partially inhibits ADAMTS 13 -mediated degradation of VWF. More particularly, the invention relates to an isolated monoclonal antibody comprising a heavy chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 3 for H-CDR1, SEQ ID NO: 4 for H-CDR2 and SEQ ID NO: 5 for H-CDR3 and a light chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 7 for L-CDR1, SEQ ID NO: 8 for L-CDR2 and SEQ ID NO: 9 for L-CDR3. Antibodies of the invention are presented to be useful in for the prevention or the treatment of bleeding episodes, such as bleeding episodes occurring in patients with aortic stenosis or patients with ventricular assist devices (VAD).


Patent
French National Center for Scientific Research and Lille University Hospital Center | Date: 2017-01-03

The present invention relates to the use of the miRNA expression profile, particularly of miR-199a-5p, and the target genes regulated thereby for the diagnosis, prognosis and use of miR-199a-5p inhibitors for treating fibroproliferative disorders.


Patent
University Paris - Sud and Lille University Hospital Center | Date: 2015-04-16

The invention relates to an isolated monoclonal antibody that specifically binds to the D4 domain of VWF, competes for binding to VWF D4 domain with ADAMTS13 and partially inhibits ADAMTS 13 -mediated degradation of VWF. More particularly, the invention relates to an isolated monoclonal antibody comprising a heavy chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 3 for H-CDR1, SEQ ID NO: 4 for H-CDR2 and SEQ ID NO: 5 for H-CDR3 and a light chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 7 for L-CDR1, SEQ ID NO: 8 for L-CDR2 and SEQ ID NO: 9 for L-CDR3. Antibodies of the invention are presented to be useful in for the prevention or the treatment of bleeding episodes, such as bleeding episodes occurring in patients with aortic stenosis or patients with ventricular assist devices (VAD).


The method allows controlling the quality of an initial RR series consisting of a plurality of (RRi) samples which are respectively a function of time intervals (ti) which separate two successive heartbeats. During this method, one resamples the RR series so as to obtain a resampled RR series, and one automatically controls the quality of the RR series by automatically calculating at least the mathematical norm value (NORME), in a sliding window, of the resampled RR series, said mathematical norm value being given by the following formula: where N is the number of RRi samples in said window.


The method is used for filtering an initial RR series of a plurality of (RRi) samples which are respectively a function of the time intervals (ti) that separate two successive heartbeats. In order to carry out this filtering, one must automatically detect in the initial RR series if one or more successive (RRi) samples are incorrect, and automatically correct in the RR series one or more of the (RRi) samples detected as being incorrect by replacing them with one or more reconstructed (RRc) samples so as to obtain an RR series. One must automatically control the quality of the RR series by counting, in a predefined sliding window, the number (NbPertub) of (RRc) samples of the RR series that were reconstructed, and/or, if applicable, the number (NbPertub) of (RRrc) samples of the RR series that were reconstructed and resampled.


Patent
Institute Pasteur Of Lille Ipl, Medizinische Hochschule Hanover and Lille University Hospital Center | Date: 2015-03-18

The present invention relates to a method for predicting mortality of a test patient with chronic heart failure comprising based on detecting the expression level of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 1 to 8. The present invention also relates to a method for predicting cardiac remodeling after myocardial infarction in a test patient based on detecting the expression level of one or more lncRNAs selected from SEQ ID NOs 1 to 8.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-14-2015 | Award Amount: 5.78M | Year: 2016

Asbestos is one of the major occupational carcinogens. The European Union has an extensive history of protecting workers and consumers against asbestos and even adopted a resolution 2012/2065(INI) on asbestos related occupational health threats and prospects for abolishing all existing asbestos last year. Although asbestos is banned, it is still massively present in the built environment. Millions of workers & consumers in the EU were, and still are, for many years exposed to asbestos fibres, despite all measures. Inhalation of even very low quantities of asbestos fibres tremendously increases the risk of developing Malignant Mesothelioma (MM). The IARC reported 8.100 MM deaths in 2010 in the EU. Despite all EU actions, MM incidence is still increasing. MM is a highly fatal disease with a poor median survival time from first signs of illness to death around 12 months despite aggressive treatments. To date there is no curative therapy for MM. MM is considered as an extremely therapy-resistant disease. Chemotherapy consisting of a combination of pemetrexed and cisplatin is considered standard of care with a median survival increase of 3 months (9-12 months). The department of pulmonary diseases of the Erasmus MC, Rotterdam, The Netherlands, in collaboration with international partners, have developed a promising personalised immunotherapy for MM with very limited adverse effects. The first clinical results show a considerably prolonged average survival with limited adverse events (24 months, twice as long). The EMA and the FDA granted this therapy Orphan Designation: autologous dendritic cells pulsed with allogeneic tumour cell lysate for the treatment of malignant mesothelioma (EU: 16 January 2014 - EU/3/13/1229; FDA US: 06 May 2014). The objective for the project is to deliver the scientific & registration package for market approval by the EMA of a novel immuno therapeutic approach to treat MM. This includes the execution of a phase II/III clinical trial.

Loading Lille University Hospital Center collaborators
Loading Lille University Hospital Center collaborators